RNTX news

Latest 1 stories · newest Nov 16, 2026

RNTX
Rein Therapeutics announces preliminary Phase 2 IPF data for LTI-03

Rein Therapeutics reported preliminary Phase 2 blinded data for LTI-03 in idiopathic pulmonary fibrosis, showing an improvement in FVC for 33% of patients. The company also provided a business update noting 75% study enrollment.

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same RNTX feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/RNTX/newsSTART FREE